Align Technology, Inc. (ALGN) — ESG & Values Scores

Environment story

The 10-K discloses no quantified Scope 1, 2, or 3 emissions data, no net-zero target year, and no verified physical decarbonization capital investments. Environmental risk disclosure is limited to generic references to climate-related supply chain/natural-disaster risk, PFAS/microplastics regulatory exposure, and CSRD compliance obligations, with no specific mitigation metrics provided. This is an informational research assessment, not investment advice.

Criticisms on file

Filing acknowledges exposure to evolving chemical-substance restrictions (e.g., PFAS, microplastics) in clear aligner materials and packaging, which may require re-design or new suppliers, but no specific fine, lawsuit, or enforcement action is documented.
Source: ALGN 10-K (FY2025), Item 1A Risk Factors, 'Current and anticipated sustainability and social laws' section

Disclosed initiatives

Manufacturing footprint restructuring

2025 restructuring included disposal of certain manufacturing assets prior to end of useful life and planned sale of the Juarez, Mexico manufacturing facility, resulting in a $23.1 million impairment charge and $76.9 million of accelerated depreciation.

Unclear environmental impact; primarily a cost/footprint optimization action, not explicitly framed as a decarbonization initiative.

Social story

No CEO-to-median-worker pay ratio, workforce diversity percentages, or supply-chain human-rights audit results are disclosed in this filing. The company reports a 2025 global workforce reduction (~3.1% headcount decline) tied to restructuring, a return-to-office mandate (5 days/week from September 2025), and acknowledges personnel in some countries are represented by works councils/trade unions, with no reported strikes or NLRB actions in the document. This is an informational research assessment, not investment advice.

Criticisms on file

Three consecutive years of restructuring plans (through Q3 2025) involving workforce reductions and a mandated return to 5-day in-office work, which the company itself flags as a risk to talent retention.
Source: ALGN 10-K (FY2025), Item 1A Risk Factors, 'If we cannot attract, motivate, train or retain personnel' section

Disclosed initiatives

Talent and succession planning disclosure

Company references training/experience investment for commercial and sales personnel and emphasis on core values (Agility, Customer, Accountability).

Governance story

The filing does not disclose board independence percentage, lobbying expenditures, or a dual-class share structure. It does disclose that the company is currently subject to antitrust, competition, and unfair-competition-related investigations, enforcement actions, or claims referenced in Note 8 'Legal Proceedings,' though no specific fine amounts or settlement terms are provided in the excerpted text. This is an informational research assessment, not investment advice.

Criticisms on file

Ongoing/potential antitrust, competition, and unfair-competition investigations, enforcement actions, or claims by governmental agencies, competitors, and others, as referenced in Note 8 'Legal Proceedings.'
Source: ALGN 10-K (FY2025), Item 1A Risk Factors, 'We are subject to antitrust and competition regulations' section

Disclosed initiatives

AI governance framework

Company states it maintains governance frameworks, internal controls, and oversight mechanisms designed to promote responsible AI development and deployment and ensure alignment with applicable laws (e.g., EU AI Act).

Intended to mitigate AI-related legal, regulatory, and reputational risk.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Align Technology, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Align Technology, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)